JAAD

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, JAAD, Risk, Annual general meeting, AAD, Skin, Abstract, Patient, Castle, GEP, Dermatology, American Academy, Pharmaceutical industry

In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.

Key Points: 
  • In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.
  • The study data demonstrate that clinicians are utilizing the DecisionDx-SCC test appropriately for patients with high-risk cutaneous squamous cell carcinoma (SCC).
  • These data support incorporating the test’s results into clinical practice to improve the accuracy of risk predictions to guide more personalized treatment plans for patients.
  • Approximately 80% of clinically tested lesions with a malignant MyPath result have sufficient biopsy tumor content for DecisionDx-Melanoma testing.

AMERICAN ACADEMY OF DERMATOLOGY INSTALLS NEW OFFICERS, BOARD MEMBERS

Retrieved on: 
Friday, March 8, 2024
Private practice, Doctor of Philosophy, Medical director, Pritzker School, Skin, University, Emory University, American College, Health policy, Diagnosis, Northwestern University, JAAD, Advisory board, MBA, Indiana Academy, Journal, Central Waqf Council, AADA, SAN, Family, Physician, Advocate, FAAD, American Academy, Birmingham School of Law, Government, AAD, Pharmacy, Society, Morehouse School of Medicine

SAN DIEGO, March 8, 2024 /PRNewswire/ -- Two new officers and five new board members will be installed immediately upon conclusion of the 2024 Annual Meeting of the American Academy of Dermatology.

Key Points: 
  • SAN DIEGO, March 8, 2024 /PRNewswire/ -- Two new officers and five new board members will be installed immediately upon conclusion of the 2024 Annual Meeting of the American Academy of Dermatology.
  • He serves as the Founder and Medical Director of Innovative Dermatology and as clinical assistant professor of dermatology at the University of Texas Southwestern.
  • Each individual listed below will serve a four-year term on the American Academy of Dermatology's Board of Directors.
  • She has served on the Board of Directors for the American College of Mohs Surgery, the American Society for Dermatology Surgery, and the Women's Dermatologic Society.

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Retrieved on: 
Monday, January 29, 2024
IGA, Patient, JAAD, FAAD, MD, Manuscript, Face, Success, Dermatitis, Scalp, Quality of life, BSA, MBA, Body surface area, Food, Journal, Disease, Safety, Study, FDA, Doctor of Philosophy, Week, Pharmaceutical industry

“Despite being very common, seborrheic dermatitis has traditionally been a disease with limited treatment options.

Key Points: 
  • “Despite being very common, seborrheic dermatitis has traditionally been a disease with limited treatment options.
  • These results highlight the effectiveness and safety of roflumilast foam, a steroid-free treatment and the first novel mechanism of action approved for seb derm in two decades.
  • Roflumilast foam also demonstrated statistically significant improvement over vehicle on all secondary endpoints, including itch, scaling, and erythema (redness).
  • The most common adverse reactions (≥1%) reported, per the prescribing information, include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

The Inner Circle Acknowledges, Josel Doyle as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology

Retrieved on: 
Monday, November 27, 2023
Winthrop University, Hospice and palliative medicine, Inner circle, NAS, JAAD, Transport, Pediatrics, Love, American Academy, Patient, Multimedia, Infection, Sleep-related breathing disorder, University of Kansas, Nuclear, Neonatal withdrawal, White lung, Stony Brook University Hospital, Hospital, Parent, Pediatrics (journal), Level 2, Education, Interior design, Nursing, Medicine, Neonatology

TOPEKA, Kan., Nov. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology.

Key Points: 
  • TOPEKA, Kan., Nov. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology.
  • Dr. Doyle pursued higher education at St. Georges University School of Medicine, earning undergraduate and medical degrees.
  • Recognized for her leadership early in her career, she also served as Chief Resident at Stony Brook University Hospital.
  • Dr. Doyle explained that neonatology is a subspecialty of pediatrics that consists of the medical care of newborn infants, especially ill and premature newborns.

Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 10, 2023
Biotechnology, Pharmaceutical, Health, Cream, Journal, Psoriasis Area and Severity Index, QD, Psoriasis, Nose, Pain, Itch, Body surface area, Oral, Abstract, Headache, Rash, Folliculitis, Pivotal, American Academy, PGA, Pharmacokinetics, Therapy, Irritation, Prescription, Stinger, Food, Composite, Incidence, PASI, Common, BSA, FDA, Convention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, JAAD, Swelling, Pharmaceutical industry, Dietary supplement, Cosmetics, Medical imaging, Dermatology

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA®(tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.

Key Points: 
  • Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA®(tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.
  • This fall, all of the abstracts will also be published in the Journal of the American Academy of Dermatology (JAAD).
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Visit fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8 DERMAVANT (1-833-762-8268).

Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Friday, March 10, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Mount Sinai, AAD, Physician, Icahn School of Medicine at Mount Sinai, GEP, American Academy, JAAD, Skin, Patient, Abstract, Computer, American Academy of Dermatology, Pharmaceutical industry, Medicine

“At Castle, we believe our tests help clinicians make more informed decisions in the care of patients with skin cancers,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.

Key Points: 
  • “At Castle, we believe our tests help clinicians make more informed decisions in the care of patients with skin cancers,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.
  • “As such, we focus strongly on continued evidence development to demonstrate where our tests can add value to clinical decision-making to improve outcomes for patients.
  • They will also be published online via the JAAD supplement in Fall 2023.
  • Lead Author: Matthew Goldberg, M.D., Castle Biosciences and Icahn School of Medicine at Mount Sinai, New York

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Cream, Shift, Janus, American Academy, Chronic, Journal, Dermatology, Conference call, Patient, Interest, Hidradenitis suppurativa, American Academy of Dermatology, AAD, Janus kinase inhibitor, Inflammation, JAK1, Use, Adolescence, Atopic dermatitis, Randomness, Post hoc analysis, Autoimmunity, Maintenance, JAAD, Conference, Abstract, HS, Safety, Cryptocurrency, Pharmaceutical industry, Communications satellite, Disease, Vitiligo, Incyte

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.
  • “The research being featured at this year’s AAD Annual Meeting highlights the potential of Incyte therapies to meet the needs of patients living with vitiligo and other serious skin conditions,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Saturday, March 18, 9:30 a.m. CT)
    Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 – Late-Breaking Research: Session 2.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2023.

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.

VTAMA® (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD

Retrieved on: 
Tuesday, June 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Cream, People, Efficiency, Acne, FDA, Patient, LTE, Vitiligo, LinkedIn, Journal, Adult, Nose, Research, American Academy, PGA, Itch, Common, Atopic dermatitis, Pain, Depression, Global Assessment of Functioning, Obesity, Risk, Therapy, Headache, Stinger, Psoriasis, Roivant Sciences, Folliculitis, Quality of life, Irritation, Rash, JD, Skin, Inflammatory bowel disease, Incidence, Hypertension, Swelling, Safety, Upper respiratory tract infection, Body surface area, Diabetes, Pharmaceutical industry, Cosmetics, MD, JAAD

VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.

Key Points: 
  • VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.
  • Newly published final data in JAAD includes efficacy outcomes, quality of life, safety, and tolerability assessments observed over long-term use of VTAMA (tapinarof) Cream, 1%.
  • The PSOARING 3 LTE study forms part of Dermavants pivotal Phase 3 plaque psoriasis clinical program for VTAMA Cream.
  • On May 24, Dermavant announced that the FDA had approved VTAMA (tapinarof) Cream, 1% for the treatment of adult plaque psoriasis.

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, Breakthrough therapy, Adult, Company, Journal, Hair, Dermatology, Food, American Academy, Hair loss, Medication, Breakthrough, Autoimmunity, Alopecia areata, FDA, JAK, Patient, JAAD, Immune system, Autoimmune disease, NASDAQ, Department, Severity, CNCE, Literature, Regulation of tobacco by the U.S. Food and Drug Administration, SALT, Yale School of Medicine, Safety, Pharmaceutical industry

The publication highlights the establishment of two doses of CTP-543 with statistically significant hair regrowth and a generally well tolerated safety profile in patients with moderate to severe alopecia areata.

Key Points: 
  • The publication highlights the establishment of two doses of CTP-543 with statistically significant hair regrowth and a generally well tolerated safety profile in patients with moderate to severe alopecia areata.
  • The robust clinical results observed in the trial supported the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and the progression of CTP-543 into the THRIVE-AA pivotal Phase 3 clinical program.
  • The Company recently reported positive topline data from the THRIVE-AA1 trial, and topline data from the THRIVE-AA2 trial is expected in the third quarter of 2022.
  • The Phase 2 trial was a randomized, double-blind, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate to severe alopecia areata.